Get the Stockscreener App
8.43
0.00%
0.00
After Hours:
8.54
0.11
+1.30%
Regenxbio Inc Stock (RGNX) Latest News
Raymond James sets $27 target for Regenxbio stock - MSN
The Potential Rise in the Price of Regenxbio Inc (RGNX) following insiders activity - Knox Daily
STATE STREET CORP Reduces Stake in Regenxbio Inc: An In-Depth Analysis - GuruFocus.com
Are Regenxbio Inc (RGNX) shares a good deal now? - US Post News
Investors in REGENXBIO (NASDAQ:RGNX) from five years ago are still down 84%, even after 11% gain this past week - Simply Wall St
Analyzing Ratios: Regenxbio Inc (RGNX)’s Financial Story Unveiled - The Dwinnex
FY2026 EPS Estimates for REGENXBIO Lifted by Leerink Partnrs - Defense World
Vanguard Group Inc Reduces Stake in Regenxbio Inc - GuruFocus.com
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 - Chicago Star Media
Objective long/short (RGNX) Report - Stock Traders Daily
Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High? - MSN
FY2024 EPS Estimates for REGENXBIO Lifted by Leerink Partnrs - Defense World
REGENXBIO (NASDAQ:RGNX) Lowered to Sell Rating by StockNews.com - MarketBeat
Leerink Partnrs Increases Earnings Estimates for REGENXBIO - MarketBeat
Analysts Offer Predictions for REGENXBIO FY2029 Earnings - MarketBeat
REGENXBIO’s (RGNX) Outperform Rating Reaffirmed at Royal Bank of Canada - Defense World
REGENXBIO's (RGNX) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
$810 Million Turned Into a Rare Disease Revolution with Japan’s Nippon Shinyaku’s and USA’s REGENXBIO’s Partnership - geneonline
Assenagon Asset Management S.A. Purchases 296,700 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
Assenagon Asset Management S.A. Has $6.62 Million Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Regenxbio and Nippon Shinyaku forge $810m gene therapy deal - MSN
(RGNX) Technical Data - Stock Traders Daily
Nippon Shinyaku, REGENXBIO partner for MPS treatments in U.S. and Asia -January 17, 2025 at 08:01 am EST - Marketscreener.com
REGENXBIO Enters Strategic Partnership with Nippon Shinyaku for Development of Gene Therapies - Defense World
Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121 - Seeking Alpha
Asia Deal Watch: Regenxbio Licenses Two MPS Gene Therapies To Nippon Shinyaku - News & Insights
REGENXBIO: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026 (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO partners with Nippon Shinyaku for MPS therapies - MSN
Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again (NASDAQ:RGNX) - Seeking Alpha
Regenxbio, Nippon Shinyaku Partner for MPS II, MPS I Gene Therapies - Contract Pharma
Regenxbio maintained at Buy rating by H.C. Wainwright post partnership announcement - Investing.com India
Regenxbio maintained at Buy by H.C. Wainwright post partnership announcement - Investing.com
Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
REGENXBIO (NASDAQ:RGNX) Receives Buy Rating from HC Wainwright - MarketBeat
Regenxbio inks MPS drugs collab with Nippon Shinyaku - The Pharma Letter
Harbor Capital Advisors Inc. Has $198,000 Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
GAMMA Investing LLC Acquires 2,510 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
AbbVie, REGENXBIO advance gene therapy for eye diseases By Investing.com - Investing.com Australia
Rockville’s RegenxBio Enters $810 Million Partnership with Japanese Firm to Launch New Treatments - The MoCoShow
Rockville’s RegenxBio strikes potential $810M deal with Japan’s Nippon Shinyaku - The Business Journals
Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku - BioPharma Dive
Regenxbio stock hits 52-week low at $7.13 amid market challenges - Investing.com Australia
RegenXBio Partners with Nippon Shinyaku on Gene Therapies - TipRanks
Regenxbio stock surges on strategic partnership deal with Nippon Shinyaku By Investing.com - Investing.com Australia
Regenxbio stock surges on strategic partnership deal with Nippon Shinyaku - Investing.com
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases - Longview News-Journal
Barclays PLC Raises Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
AbbVie, REGENXBIO advance gene therapy for eye diseases - Investing.com India
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):